CL2020001090A1 - Compuesto de pirimidina como inhibidor de las janocinasas. - Google Patents

Compuesto de pirimidina como inhibidor de las janocinasas.

Info

Publication number
CL2020001090A1
CL2020001090A1 CL2020001090A CL2020001090A CL2020001090A1 CL 2020001090 A1 CL2020001090 A1 CL 2020001090A1 CL 2020001090 A CL2020001090 A CL 2020001090A CL 2020001090 A CL2020001090 A CL 2020001090A CL 2020001090 A1 CL2020001090 A1 CL 2020001090A1
Authority
CL
Chile
Prior art keywords
inhibitor
compound
janokinase
pyrimidine compound
prepared
Prior art date
Application number
CL2020001090A
Other languages
English (en)
Inventor
Ryan Hudson
Gary E L Brandt
Marta Dabros
Robert Murray Mckinnell
Jerry Nzerem
Jennifer Kozak
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of CL2020001090A1 publication Critical patent/CL2020001090A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Dental Preparations (AREA)

Abstract

LA INVENCIÓN PROPORCIONA UN COMPUESTO DE LA FÓRMULA (I), O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE ESTE, QUE ES UN INHIBIDOR DE LAS JANOCINASAS (JAK). LA INVENCIÓN TAMBIÉN PROPORCIONA COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN DICHO COMPUESTO, UNA FORMA CRISTALINA, MÉTODOS DE USO DE DICHO COMPUESTO PARA TRATAR ENFERMEDADES INFLAMATORIAS DE LA PIEL Y OTRAS ENFERMEDADES, Y PROCESOS Y PRODUCTOS INTERMEDIOS ÚTILES PARA PREPARAR DICHO COMPUESTO.
CL2020001090A 2017-10-27 2020-04-23 Compuesto de pirimidina como inhibidor de las janocinasas. CL2020001090A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762577852P 2017-10-27 2017-10-27

Publications (1)

Publication Number Publication Date
CL2020001090A1 true CL2020001090A1 (es) 2020-08-21

Family

ID=64277858

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001090A CL2020001090A1 (es) 2017-10-27 2020-04-23 Compuesto de pirimidina como inhibidor de las janocinasas.

Country Status (38)

Country Link
US (7) US10308646B2 (es)
EP (1) EP3672965B1 (es)
JP (1) JP7218364B2 (es)
KR (1) KR102613503B1 (es)
CN (1) CN111247142B (es)
AR (1) AR113803A1 (es)
AU (1) AU2018354370B2 (es)
BR (1) BR112020008015A2 (es)
CA (1) CA3074034A1 (es)
CL (1) CL2020001090A1 (es)
CR (1) CR20200180A (es)
CU (1) CU24671B1 (es)
DK (1) DK3672965T3 (es)
DO (1) DOP2020000083A (es)
EA (1) EA202091016A1 (es)
EC (1) ECSP20023795A (es)
ES (1) ES2932526T3 (es)
GE (2) GEAP202115340A (es)
HR (1) HRP20221221T1 (es)
HU (1) HUE060401T2 (es)
IL (1) IL274037B2 (es)
LT (1) LT3672965T (es)
MA (1) MA49956B1 (es)
MD (1) MD3672965T2 (es)
MX (1) MX2020004255A (es)
NI (1) NI202000032A (es)
PE (1) PE20201495A1 (es)
PH (1) PH12020500528A1 (es)
PL (1) PL3672965T3 (es)
PT (1) PT3672965T (es)
RS (1) RS63608B1 (es)
SG (1) SG11202001706RA (es)
SI (1) SI3672965T1 (es)
SM (1) SMT202200409T1 (es)
TW (1) TWI789446B (es)
UA (1) UA125130C2 (es)
WO (1) WO2019084383A1 (es)
ZA (1) ZA202001641B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20221221T1 (hr) 2017-10-27 2022-12-09 Theravance Biopharma R&D Ip, Llc Pirimidinski spoj kao inhibitor jak kinaze
JP2022510980A (ja) * 2018-11-30 2022-01-28 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 ヘテロ芳香族誘導体調節因子、その製造方法及び使用
TW202106681A (zh) * 2019-04-24 2021-02-16 美商施萬生物製藥研發Ｉｐ有限責任公司 用於治療皮膚疾病之嘧啶jak抑制劑
EP3958969B1 (en) 2019-04-24 2024-01-10 Theravance Biopharma R&D IP, LLC Ester and carbonate pyrimidine compounds as jak kinase inhibitors
BR112023001283A2 (pt) 2020-07-28 2023-02-14 Arcutis Biotherapeutics Inc Composição farmacêutica tópica; método para tratar uma doença, distúrbio ou afecção inflamatória de pele em um indivíduo que necessita do mesmo; e método para intensificar a penetração em pele em um indivíduo de uma formulação farmacêutica tópica
AU2021333760A1 (en) * 2020-08-26 2023-04-06 Nalo Therapeutics Modulators of Myc family proto-oncogene protein
EP4225438A4 (en) * 2020-10-08 2025-02-19 Icahn School of Medicine at Mount Sinai COMPOSITIONS FOR THE TREATMENT OF ALOPECIA AREATA, BIOMARKERS FOR TREATMENT SUCCESS, AND METHODS OF USE THEREOF
TW202311256A (zh) * 2021-06-18 2023-03-16 美商基利科學股份有限公司 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑
JP2024539280A (ja) 2021-10-25 2024-10-28 カイメラ セラピューティクス， インコーポレイテッド Ｔｙｋ２分解剤およびそれらの使用
KR20240125610A (ko) 2021-12-15 2024-08-19 아큐티스 바이오테라퓨틱스, 인크. Shr0302의 안정된 제형
CN114246938A (zh) * 2022-01-25 2022-03-29 中山大学中山眼科中心 Il-4在制备用于治疗视网膜变性疾病药物中的应用
CN115487301B (zh) * 2022-11-08 2023-07-07 四川大学华西医院 Il-13抑制剂在制备延缓或治疗视网膜色素变性的药物中的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1317450B1 (en) 2000-09-15 2006-11-22 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
NZ526472A (en) 2000-12-21 2004-04-30 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
JP2008525422A (ja) * 2004-12-23 2008-07-17 ファイザー・プロダクツ・インク 抗癌剤として有用な複素芳香族誘導体
CA2629781A1 (en) 2005-11-16 2007-05-24 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
JP2009541480A (ja) 2006-06-30 2009-11-26 アストラゼネカ アクチボラグ 癌の治療において有用なピリミジン誘導体
EP2043651A2 (en) 2006-07-05 2009-04-08 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
BR112014015549A8 (pt) 2011-12-22 2017-07-04 Hoffmann La Roche composto, método de inibição da atividade pak1, método para o tratamento, processo, composição, utilização de um composto e invenção
WO2015094803A1 (en) * 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
NO2721710T3 (es) * 2014-08-21 2018-03-31
JP2017535520A (ja) * 2014-09-30 2017-11-30 ハンミ・ファイン・ケミカル・カンパニー・リミテッドＨａｎｍｉ Ｆｉｎｅ Ｃｈｅｍｉｃａｌ Ｃｏ．， Ｌｔｄ． 高純度の（ｒ）−９−［２−（ホスホノメトキシ）プロピル］アデニンの製造方法
JP6692836B2 (ja) * 2015-05-28 2020-05-13 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物
WO2017044434A1 (en) * 2015-09-11 2017-03-16 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
MX377180B (es) * 2016-04-28 2025-03-07 Theravance Biopharma R&D Ip Llc Compuestos de pirimidina como inhibidores de la quinasa jak.
HRP20221221T1 (hr) * 2017-10-27 2022-12-09 Theravance Biopharma R&D Ip, Llc Pirimidinski spoj kao inhibitor jak kinaze
EP3958969B1 (en) 2019-04-24 2024-01-10 Theravance Biopharma R&D IP, LLC Ester and carbonate pyrimidine compounds as jak kinase inhibitors
TW202106681A (zh) 2019-04-24 2021-02-16 美商施萬生物製藥研發Ｉｐ有限責任公司 用於治療皮膚疾病之嘧啶jak抑制劑

Also Published As

Publication number Publication date
AU2018354370B2 (en) 2023-04-27
GEAP202115340A (en) 2021-08-10
ES2932526T3 (es) 2023-01-20
MX2020004255A (es) 2020-07-29
EP3672965B1 (en) 2022-09-07
US20220396573A1 (en) 2022-12-15
CU20200053A7 (es) 2021-03-11
CR20200180A (es) 2020-08-12
WO2019084383A1 (en) 2019-05-02
MA49956A (fr) 2020-07-01
US10988470B2 (en) 2021-04-27
US10562894B2 (en) 2020-02-18
PT3672965T (pt) 2022-09-29
US20200369660A1 (en) 2020-11-26
BR112020008015A2 (pt) 2020-10-27
PE20201495A1 (es) 2020-12-29
PL3672965T3 (pl) 2023-01-16
UA125130C2 (uk) 2022-01-12
US20190127364A1 (en) 2019-05-02
EA202091016A1 (ru) 2020-07-17
DK3672965T3 (da) 2022-10-03
MD3672965T2 (ro) 2022-12-31
TW201930304A (zh) 2019-08-01
CU24671B1 (es) 2023-07-12
ECSP20023795A (es) 2020-06-30
SG11202001706RA (en) 2020-03-30
HUE060401T2 (hu) 2023-02-28
US20190241555A1 (en) 2019-08-08
JP7218364B2 (ja) 2023-02-06
CA3074034A1 (en) 2019-05-02
RS63608B1 (sr) 2022-10-31
CN111247142B (zh) 2022-12-02
US11420965B2 (en) 2022-08-23
EP3672965A1 (en) 2020-07-01
HRP20221221T1 (hr) 2022-12-09
SMT202200409T1 (it) 2022-11-18
US10308646B2 (en) 2019-06-04
IL274037B1 (en) 2023-07-01
US12172994B2 (en) 2024-12-24
US10774080B2 (en) 2020-09-15
IL274037B2 (en) 2023-11-01
AR113803A1 (es) 2020-06-10
TWI789446B (zh) 2023-01-11
US11814377B2 (en) 2023-11-14
MA49956B1 (fr) 2022-11-30
IL274037A (en) 2020-06-30
JP2021501151A (ja) 2021-01-14
ZA202001641B (en) 2021-04-28
DOP2020000083A (es) 2020-08-15
PH12020500528A1 (en) 2021-06-07
SI3672965T1 (sl) 2022-11-30
KR102613503B1 (ko) 2023-12-13
US20210214349A1 (en) 2021-07-15
CN111247142A (zh) 2020-06-05
US20240158389A1 (en) 2024-05-16
LT3672965T (lt) 2022-10-10
NI202000032A (es) 2020-10-09
US20200140430A1 (en) 2020-05-07
KR20200078517A (ko) 2020-07-01
GEP20227344B (en) 2022-01-25
AU2018354370A1 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
CL2020001090A1 (es) Compuesto de pirimidina como inhibidor de las janocinasas.
CO2019011809A2 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
CO2018005640A2 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
CO2017012267A2 (es) Compuestos de naftiridina como inhibidores de la quinasa jak
MX2018015625A (es) Compuestos y composiciones para inhibir la actividad de shp2.
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
BR112021007788A8 (pt) Composto inibidor de jak 2-azabiciclo hexano
EA201791576A1 (ru) Ингибитор jak
GT201600147A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
CL2021000515A1 (es) Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
MX2020004283A (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
UY36713A (es) Triazoles para el tratamiento de enfermedades desmielinizantes
UA120927C2 (uk) Тритерпеноїди, заміщені в положенні 3 неароматичним кільцем, яке несе галогеналкільний замісник, з інгібуючою активністю щодо дозрівання віл
EA201790016A1 (ru) АНАЛОГ ПИРИДИНО[1,2-a]ПИРИМИДОНА, ПРИМЕНЯЕМЫЙ В КАЧЕСТВЕ ИНГИБИТОРА PI3K
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
MX2019006612A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).
CO2019001644A2 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
MX2018010727A (es) Acido (2s,4r)-5-(5&#39;-cloro-2&#39;-fluoro-[1,1&#39;-bifenil]-4-il)-2-(etoxim etil)-4-(3-hidroxiisoxazol-5-carboxamido)-2-metilpentanoico cristalino, y sus usos.
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.